Research Topics
| Lauren B MarangellSummaryAffiliation: Eli Lilly and Company Country: USA Publications
| Collaborators
|
Detail Information
Publications
Current issues: women and bipolar disorderLauren B Marangell
Mood Disorders Center, Menninger Department of Psychiatry, Baylor College of Medicine Houston, Texas, USA
Dialogues Clin Neurosci 10:229-38. 2008..In order to best address these issues, clinicians must be familiar with the data and collaborate with the patient to assess risks and benefits for the individual women and her family...- The functional impact of subsyndromal depressive symptoms in bipolar disorder: data from STEP-BDLauren B Marangell
Mood Disorders Center, Menninger Department of Psychiatry, Baylor College of Medicine, Houston, TX, United States
J Affect Disord 114:58-67. 2009..This report describes baseline characteristics and functional outcomes of subjects who have prospectively observed subsyndromal symptoms after a major depressive episode (MDE)... 
Case-control analyses of the impact of pharmacotherapy on prospectively observed suicide attempts and completed suicides in bipolar disorder: findings from STEP-BDLauren B Marangell
Mood Disorders Center, Menninger Department of Psychiatry, Baylor College of Medicine and South Central Mental Illness Research and Education Core, Department of Veterans Affairs, Houston, Tex, USA
J Clin Psychiatry 69:916-22. 2008....- A 1-year pilot study of vagus nerve stimulation in treatment-resistant rapid-cycling bipolar disorderLauren B Marangell
Mood Disorders Center, Menninger Department of Psychiatry, Baylor College of Medicine, and Department of Veterans Affairs, Houston, Texas, USA
J Clin Psychiatry 69:183-9. 2008..The aim of the present study was to investigate the efficacy of VNS in a group of patients with treatment-resistant rapid-cycling bipolar disorder (RCBD) who were excluded from previous trials... 
Comparative pain and mood effects in patients with comorbid fibromyalgia and major depressive disorder: secondary analyses of four pooled randomized controlled trials of duloxetineLauren B Marangell
Lilly USA, LLC, Lilly Corporate Center, Indianapolis, IN 46285, USA
Pain 152:31-7. 2011..Hence, both direct and indirect analgesic and antidepressant properties appear to be relevant for the treatment of these comorbid patients with duloxetine...- Omega-3 fatty acids in bipolar disorder: clinical and research considerationsLauren B Marangell
Mood Disorders Center, Menninger Department of Psychiatry, Baylor College of Medicine, Houston, TX, USA
Prostaglandins Leukot Essent Fatty Acids 75:315-21. 2006..Our pilot trial of DHA in women who plan to stop conventional psychotropics in order to conceive suggests that such trials are feasible... - A pragmatic 12-week, randomized trial of duloxetine versus generic selective serotonin-reuptake inhibitors in the treatment of adult outpatients in a moderate-to-severe depressive episodeJames Michael Martinez
Lilly USA, LLC, Lilly Corporate Center, Indianapolis, IN 46285, USA
Int Clin Psychopharmacol 27:17-26. 2012..Study demographics suggest a more generalizable racial and ethnic population than is typical in randomized clinical trials... - A randomized placebo-controlled trial of duloxetine in patients with major depressive disorder and associated painful physical symptomsPaula J Gaynor
Eli Lilly and Company, Indianapolis, IN, USA
Curr Med Res Opin 27:1849-58. 2011..Duloxetine has demonstrated efficacy in treating both MDD and certain other painful conditions. This randomized, double-blind clinical trial assessed the effects of duloxetine in patients with both MDD and MDD-associated physical pain... - Prospective predictors of suicide and suicide attempts in 1,556 patients with bipolar disorders followed for up to 2 yearsLauren B Marangell
Mood Disorders Center, Menninger Department of Psychiatry, Baylor College of Medicine and the Department of Veterans Affairs, VISN 16 MIRECC, Houston, TX 77030, USA
Bipolar Disord 8:566-75. 2006.... - Baseline predictors of serious adverse events at one year among patients with bipolar disorder in STEP-BDJames M Martinez
Mood Disorders Center, Menninger Department of Psychiatry, Baylor College of Medicine, Ben Taub Hospital, Houston, TX 77030, USA
Psychiatr Serv 56:1541-8. 2005..Little is known about serious adverse events that occur in the context of clinical care for bipolar disorder. This study examined predictors of serious adverse events in a large cohort of patients with bipolar disorder... - The importance of subsyndromal symptoms in bipolar disorderLauren B Marangell
Mood Disorders Center, Baylor College of Medicine, and the South Central Mental Illness Research, Education, and Clinical Center of the Department of Veterans Affairs, Houston, Tex, USA
J Clin Psychiatry 65:24-7. 2004..In addition, the use of subsyndromal symptoms to broaden the diagnostic criteria for bipolar disorder is receiving increased attention. This article reviews and discusses these important issues... - The efficacy and tolerability of duloxetine in the treatment of anxious versus non-anxious depression: a post-hoc analysis of an open-label outpatient studyMaurizio Fava
Department of Psychiatry, Massachusetts General Hospital, Boston, MA, and Menninger Department of Psychiatry, Baylor College of Medicine, Houston, TX, USA
Ann Clin Psychiatry 19:187-95. 2007..This study compares the efficacy and tolerability of 12 weeks of open-label duloxetine in adult outpatients with anxious versus non-anxious depression... - Prescription patterns of psychotropic medications in elderly compared with younger participants who achieved a "recovered" status in the systematic treatment enhancement program for bipolar disorderRayan K Al Jurdi
Department of Psychiatry, Baylor College of Medicine, Houston, Texas, USA
Am J Geriatr Psychiatry 16:922-33. 2008..This study compares prescription patterns between young adults and elderly with bipolar disorder who achieved a recovery status during the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD)... - Omega-3 fatty acids for the prevention of postpartum depression: negative data from a preliminary, open-label pilot studyLauren B Marangell
Department of Psychiatry, Baylor College of Medicine, Houston, Texas 77030, USA
Depress Anxiety 19:20-3. 2004..Controlled studies are lacking... - Lamotrigine treatment of bipolar disorder: data from the first 500 patients in STEP-BDLauren B Marangell
Mood Disorders Program, Department of Psychiatry, Baylor College of Medicine, Houston, TX 77030, USA
Bipolar Disord 6:139-43. 2004..To describe the frequency and correlates of lamotrigine therapy among the first 500 patients enrolled into the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) study... - Vagus nerve stimulation: current use and potential applications in child and adolescent psychiatryJames M Martinez
Menninger Department of Psychiatry, Baylor College of Medicine, 6655 Travis Road, Suite 560, Houston, TX 77030, USA
Child Adolesc Psychiatr Clin N Am 14:177-91, viii. 2005..This intervention also holds promise as a potential treatment in children and adolescents, although research is currently lacking... - A double-blind, placebo-controlled study of the omega-3 fatty acid docosahexaenoic acid in the treatment of major depressionLauren B Marangell
Mood Disorders Center, Department of Psychiatry, Baylor College of Medicine, Suite 560, 6655 Travis Road, Houston, TX 77030, USA
Am J Psychiatry 160:996-8. 2003..This study was an evaluation of the omega-3 fatty acid docosahexaenoic acid (DHA) for the treatment of major depression... - Olanzapine in the treatment of apathy in previously depressed participants maintained with selective serotonin reuptake inhibitors: an open-label, flexible-dose studyLauren B Marangell
Mood Disorders Center, Department of Psychiatry, Baylor College of Medicine, Houston, Tex 77030, USA
J Clin Psychiatry 63:391-5. 2002..We report a clinical trial of olanzapine in the treatment of prominent apathy in the absence of depression in patients on long-term treatment with selective serotonin reuptake inhibitors (SSRIs) for nonpsychotic major depression... - Duloxetine versus placebo in the treatment of major depressive disorder and associated painful physical symptoms: a replication studyPaula J Gaynor
Eli Lilly and Company, Indianapolis, IN, USA
Curr Med Res Opin 27:1859-67. 2011..Duloxetine has demonstrated efficacy in treating MDD and other certain painful conditions; this study specifically evaluated patients with both MDD and MDD-associated pain... - Assessment of depressive symptoms and functional outcomes in patients with major depressive disorder treated with duloxetine versus placebo: primary outcomes from two trials conducted under the same protocolTina Marie Myers Oakes
Lilly USA, LLC, Indianapolis, Indiana 46201, USA
Hum Psychopharmacol 27:47-56. 2012..Return of functional ability is a central goal in the treatment of major depressive disorder. We conducted two trials with the same protocol that was designed to assess functioning after 8 Weeks of treatment with duloxetine... - Use of treatment algorithms for depressionMadhukar H Trivedi
Mood Disorders Program and Clinic, Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX, USA
J Clin Psychiatry 67:1458-65. 2006 - Vagus nerve stimulation (VNS) for major depressive episodes: one year outcomesLauren B Marangell
Department of Psychiatry, Baylor College of Medicine, One Baylor Plaza, BCM 350, Houston, TX 77030, USA
Biol Psychiatry 51:280-7. 2002..CONCLUSIONS: Longer-term vagus nerve stimulation treatment was associated with sustained symptomatic benefit and sustained or enhanced functional status in this naturalistic follow-up study... - A cross-national relationship between sugar consumption and major depression?Arthur N Westover
Mood Disorders Center MDOC, Department of Psychiatry, Baylor College of Medicine, Houston, Texas, USA
Depress Anxiety 16:118-20. 2002..Possible relationships between sugar consumption, beta-endorphins, and oxidative stress are discussed... - Comprehensive review of factors implicated in the heterogeneity of response in depressionGebra Cuyun Carter
Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana, USA
Depress Anxiety 29:340-54. 2012..The goal of this study was to review the literature and attempt to identify nongenetic factors potentially predictive of overall response to depression treatments... - Long-term implications of early onset in bipolar disorder: data from the first 1000 participants in the systematic treatment enhancement program for bipolar disorder (STEP-BD)Roy H Perlis
Partners Bipolar Treatment Center at Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA
Biol Psychiatry 55:875-81. 2004..CONCLUSIONS: Very early or early onset of bipolar disorder might herald a more severe disease course in terms of chronicity and comorbidity. Whether early intervention might modify this risk merits further investigation... - Vagus nerve stimulation for treatment-resistant depression: a randomized, controlled acute phase trialA John Rush
Department of Psychiatry, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390, USA
Biol Psychiatry 58:347-54. 2005..Vagus nerve stimulation (VNS) alters both concentrations of neurotransmitters or their metabolites and functional activity of central nervous system regions dysregulated in mood disorders. An open trial has suggested efficacy... - Are antidepressants associated with new-onset suicidality in bipolar disorder? A prospective study of participants in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD)Mark S Bauer
Providence Veterans Affairs Medical Center and the Department of Psychiatry and Human Behavior, Brown University, VAMC 116R, 830 Chalkstone Avenue, Providence, R I 02908 4799, USA
J Clin Psychiatry 67:48-55. 2006..However, few data are available to inform the suicidality risk assessment of antidepressant use specifically in bipolar disorder... - Effects of 12 months of vagus nerve stimulation in treatment-resistant depression: a naturalistic studyA John Rush
Department of Psychiatry, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390, USA
Biol Psychiatry 58:355-63. 2005..The need for effective, long-term treatment for recurrent or chronic, treatment-resistant depression is well established... - A one-year comparison of vagus nerve stimulation with treatment as usual for treatment-resistant depressionMark S George
Department of Psychiatry, Medical University of South Carolina, 67 President Street 502 N, Charleston, SC 29425, USA
Biol Psychiatry 58:364-73. 2005..To better understand these effects on long-term outcome, we compared 12-month VNS+TAU outcomes with those of a comparable TRD group... - Two-year outcome of vagus nerve stimulation (VNS) for treatment of major depressive episodesZiad Nahas
Brain Stimulation Laboratory, Department of Psychiatry, Medical University of South Carolina, Charleston, SC 29403, USA
J Clin Psychiatry 66:1097-104. 2005..We examined the effects of adjunctive VNS over 24 months in this cohort... - Current suicide ideation and prior suicide attempts of bipolar patients as influences on caregiver burdenCheryl A Chessick
Department of Psychiatry, University of Colorado Health Sciences Center, Denver, Colorado 80220, USA
Suicide Life Threat Behav 37:482-91. 2007..Levels of depression in caregivers varied with whether the caregiver was a spouse or a parent, and whether patients had a history of suicide attempts, current suicidal ideation, or both... - Psychosocial treatments for bipolar depression: a 1-year randomized trial from the Systematic Treatment Enhancement ProgramDavid J Miklowitz
Department of Psychology, University of Colorado, Boulder, CO 80309 0345, USA
Arch Gen Psychiatry 64:419-26. 2007..Psychosocial interventions have been shown to enhance pharmacotherapy outcomes in bipolar disorder... - Treatment-resistant bipolar depression: a STEP-BD equipoise randomized effectiveness trial of antidepressant augmentation with lamotrigine, inositol, or risperidoneAndrew A Nierenberg
Massachusetts General Hospital Bipolar Clinic and Research Program, Suite 580, 50 Staniford Street, Boston, MA 02114, USA
Am J Psychiatry 163:210-6. 2006..This study represents the first randomized trial of competing options for treatment-resistant bipolar depression and assesses the effectiveness and safety of antidepressant augmentation with lamotrigine, inositol, and risperidone... - Predictors of recurrence in bipolar disorder: primary outcomes from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD)Roy H Perlis
Bipolar Clinical and Research Program, Massachusetts General Hospital, ACC 812, 15 Parkman Street, Boston, MA 02114, USA
Am J Psychiatry 163:217-24. 2006..The authors looked for the features associated with risk of recurrence... - Brief report: paroxetine in younger and adult individuals at high risk for suicideMark S Bauer
Department of Psychiatry, Brown University, USA
Psychopharmacol Bull 39:31-7. 2006..In fact, the younger group showed a trend for decreased suicidality (P = .13). Thus, increased suicidality risk with paroxetine exposure does not extend to this other high-risk mood disordered population, even among younger individuals... - Intensive psychosocial intervention enhances functioning in patients with bipolar depression: results from a 9-month randomized controlled trialDavid J Miklowitz
Department of Psychology, University of Colorado, Boulder, CO 80309 0345, USA
Am J Psychiatry 164:1340-7. 2007..In a randomized trial, the authors examined the impact of intensive psychosocial treatment plus pharmacotherapy on the functional outcomes of patients with bipolar disorder over the 9 months following a depressive episode... - Durability of antidepressant response to vagus nerve stimulation (VNS)Harold A Sackeim
Departments of Biological Psychiatry, New York State Psychiatric Institute, New York, NY 10032, USA
Int J Neuropsychopharmacol 10:817-26. 2007..Yet patients who showed substantial clinical benefit maintained the improvement at remarkably high rates. This durability of benefit was not attributable to alterations in other treatments... - How blind is double-blind? A study of fish oil versus placeboKaren E Damico
Psychopharmacology Research Laboratory, Center for the Development of Novel and Natural Treatments for Mood Disorders, McLean Hospital, Belmont, MA 02478, USA
Prostaglandins Leukot Essent Fatty Acids 66:393-5. 2002..The results suggest that altering subjects' expectations could further improve the validity of the double-blind... - Effectiveness of adjunctive antidepressant treatment for bipolar depressionGary S Sachs
Bipolar Clinic and Research Program, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
N Engl J Med 356:1711-22. 2007..Our study was designed to determine whether adjunctive antidepressant therapy reduces symptoms of bipolar depression without increasing the risk of mania... - Serotonin gene polymorphisms and bipolar I disorder: focus on the serotonin transporterHader A Mansour
Department of Psychiatry, University of Pittsburgh School of Medicine, Western Psychiatric Institute and Clinic, 3811 O Hara Street, Pittsburgh, PA 15213, U S A
Ann Med 37:590-602. 2005..Our analyses do not support association between SLC6A4 and BDI families. Further studies using sub-groups of BDI are worthwhile... - Gender differences in bipolar disorder: retrospective data from the first 500 STEP-BD participantsClaudia F Baldassano
Bipolar Disorders Program, Department of Psychiatry, University of Pennsylvania, Philadelphia, PA, USA
Bipolar Disord 7:465-70. 2005..To examine gender differences in a large sample of patients with bipolar illness... - Increased rate of non-right-handedness in patients with bipolar disorderCecylia Nowakowska
J Clin Psychiatry 69:866-7. 2008 - Whole-genome association study of bipolar disorderP Sklar
Center for Human Genetic Research, Massachusetts General Hospital, Boston, MA 02114, USA
Mol Psychiatry 13:558-69. 2008..Given the heritability of BP disorder, the lack of agreement between studies emphasizes that susceptibility alleles are likely to be modest in effect size and require even larger samples for detection... - Overweight and obesity in bipolar disordersPo W Wang
Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, 401 Quarry Road, Room 2117, CA 94305-5723, USA
J Psychiatr Res 40:762-4. 2006